Jody Beck
Adult Health · Washington, DCNPI 1346727815
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,080, 7.4 times the $147 reported in 2023.
Across 76 payments — averaging $24.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$282
- Merck$251
- AstraZeneca$143
- Regeneron Healthcare Solutions, Inc.$139
- Johnson & Johnson$120
- Incyte Corporation$94
- plus $806 from 23 others
What the payments were for
- Food & beverage$1,836100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 11 | $282 |
| Merck | 9 | $251 |
| AstraZeneca(2 entities) | 6 | $143 |
| Regeneron Healthcare Solutions, Inc. | 6 | $139 |
| Johnson & Johnson | 5 | $120 |
| Incyte Corporation | 5 | $94 |
| Daiichi Sankyo Inc. | 3 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $85 |
| AbbVie | 3 | $72 |
| GSK | 2 | $69 |
| Genentech USA, Inc. | 3 | $63 |
| Eisai Inc. | 2 | $53 |
| Beigene USA, Inc. | 2 | $46 |
| Pharmaessentia USA Corporation | 1 | $32 |
| Bayer | 1 | $32 |
| Syndax Pharmaceuticals, Inc. | 1 | $28 |
| Exelixis Inc. | 1 | $25 |
| Monteris Medical Corporation | 1 | $24 |
| Mirati Therapeutics, Inc. | 1 | $22 |
| Pfizer | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| Immunocore Limited | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Deciphera Pharmaceuticals Inc. | 1 | $14 |
| Iovance Biotherapeutics, Inc. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
How this compares
$1,836 in reported general payments places this provider in the 85th percentile of 63 adult health providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other adult health in Washington
- Maureen MoriartyWashington$237K
- Monica BaenaWashington$12K
- Barbara WilmarthWashington$10K
- Payal KadakiaWashington$6K
- Aimee ChappellWashington$6K
- Sarah BottomleyWashington$5K
- Rachel BarishWashington$4K
- Jillian ThompsonWashington$3K
- Tracy HolzmanWashington$3K
- Jude NjokuWashington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.